403 related articles for article (PubMed ID: 32998732)
1. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
[TBL] [Abstract][Full Text] [Related]
3. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Husain M; Bain SC; Jeppesen OK; Lingvay I; Sørrig R; Treppendahl MB; Vilsbøll T
Diabetes Obes Metab; 2020 Mar; 22(3):442-451. PubMed ID: 31903692
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
Husain M; Consoli A; De Remigis A; Pettersson Meyer AS; Rasmussen S; Bain S
Cardiovasc Diabetol; 2022 Apr; 21(1):64. PubMed ID: 35484580
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
7. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
8. Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
Jendle J; Birkenfeld AL; Polonsky WH; Silver R; Uusinarkaus K; Hansen T; Håkan-Bloch J; Tadayon S; Davies MJ
Diabetes Obes Metab; 2019 Oct; 21(10):2315-2326. PubMed ID: 31215727
[TBL] [Abstract][Full Text] [Related]
9. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB
Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418
[TBL] [Abstract][Full Text] [Related]
10. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
[TBL] [Abstract][Full Text] [Related]
11. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Rossing P; Bain SC; Bosch-Traberg H; Sokareva E; Heerspink HJL; Rasmussen S; Mellbin LG
Cardiovasc Diabetol; 2023 Aug; 22(1):220. PubMed ID: 37620807
[TBL] [Abstract][Full Text] [Related]
12. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
Mosenzon O; Capehorn MS; De Remigis A; Rasmussen S; Weimers P; Rosenstock J
Cardiovasc Diabetol; 2022 Sep; 21(1):172. PubMed ID: 36056351
[TBL] [Abstract][Full Text] [Related]
13. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Verma S; Al-Omran M; Leiter LA; Mazer CD; Rasmussen S; Saevereid HA; Sejersten Ripa M; Bonaca MP
Diabetes Obes Metab; 2022 Jul; 24(7):1288-1299. PubMed ID: 35332654
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Bain SC; Mosenzon O; Arechavaleta R; Bogdański P; Comlekci A; Consoli A; Deerochanawong C; Dungan K; Faingold MC; Farkouh ME; Franco DR; Gram J; Guja C; Joshi P; Malek R; Merino-Torres JF; Nauck MA; Pedersen SD; Sheu WH; Silver RJ; Tack CJ; Tandon N; Jeppesen OK; Strange M; Thomsen M; Husain M
Diabetes Obes Metab; 2019 Mar; 21(3):499-508. PubMed ID: 30284349
[TBL] [Abstract][Full Text] [Related]
16. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
Verma S; Fainberg U; Husain M; Rasmussen S; Rydén L; Ripa MS; Buse JB
Diabetes Obes Metab; 2021 Jul; 23(7):1677-1680. PubMed ID: 33606902
[TBL] [Abstract][Full Text] [Related]
17. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
Verma S; Bain SC; Monk Fries T; Mazer CD; Nauck MA; Pratley RE; Rasmussen S; Saevereid HA; Zinman B; Buse JB
Diabetes Obes Metab; 2019 Jul; 21(7):1745-1751. PubMed ID: 30851070
[TBL] [Abstract][Full Text] [Related]
18. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
19. Oral Semaglutide Reduces HbA
Pratley RE; Crowley MJ; Gislum M; Hertz CL; Jensen TB; Khunti K; Mosenzon O; Buse JB
Diabetes Ther; 2021 Apr; 12(4):1099-1116. PubMed ID: 33660198
[TBL] [Abstract][Full Text] [Related]
20. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
